{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:40:00Z","timestamp":1790664000712,"version":"4.1.0"},"reference-count":64,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2022,5,3]]},"abstract":"<jats:p>Background: Monoclonal antibodies (mAbs) are currently among the most investigated targets for potential disease-modifying therapies in Alzheimer\u2019s disease (AD). Objective: Our objectives were to identify all registered trials investigating mAbs in MCI due to AD or AD at any stage, retrieve available published and unpublished data from all registered trials, and analyze data on safety and efficacy outcomes. Methods: A systematic search of all registered trials on ClinicalTrials.gov and EUCT was performed. Available results were searched on both platforms and on PubMed, ISI Web of Knowledge, and The Cochrane Library. Results: Overall, 101 studies were identified on 27 mAbs. Results were available for 50 trials investigating 12 mAbs. For 18 trials, data were available from both published and unpublished sources, for 21 trials only from published sources, and for 11 trials only from unpublished sources. Meta-analyses of amyloid-related imaging abnormalities (ARIA) events showed overall risk ratios of 10.65 for ARIA-E and of 1.75 for ARIA-H. The meta-analysis of PET-SUVR showed an overall significant effect of mAbs in reducing amyloid (SMD \u20130.88), but when considering clinical efficacy, data on CDR-SB showed that treated patients had a statistically significant but clinically non-relevant lower worsening (MD \u20130.15). Conclusion: Our results suggest that the risk-benefit profile of mAbs remains unclear. Research should focus on clarifying the effect of amyloid on cognitive decline, providing data on treatment response rate, and accounting for minimal clinically important difference. Research on mAbs should also investigate the possible long-term impact of ARIA events, including potential factors predicting their onset.<\/jats:p>","DOI":"10.3233\/jad-220046","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T13:55:25Z","timestamp":1646747725000},"page":"101-129","source":"Crossref","is-referenced-by-count":92,"title":["Safety and Efficacy of Monoclonal Antibodies for Alzheimer\u2019s Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials"],"prefix":"10.1177","volume":"87","author":[{"given":"Eleonora","family":"Lacorte","sequence":"first","affiliation":[{"name":"National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ancidoni","sequence":"additional","affiliation":[{"name":"National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy"},{"name":"Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Zaccaria","sequence":"additional","affiliation":[{"name":"Department of Human Neuroscience, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Remoli","sequence":"additional","affiliation":[{"name":"National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Tariciotti","sequence":"additional","affiliation":[{"name":"Neurosurgery Department, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Bellomo","sequence":"additional","affiliation":[{"name":"National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sciancalepore","sequence":"additional","affiliation":[{"name":"National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Corbo","sequence":"additional","affiliation":[{"name":"Department of Neurorehabilitation Sciences, Casa Cura Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia L.","family":"Lombardo","sequence":"additional","affiliation":[{"name":"National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Bacigalupo","sequence":"additional","affiliation":[{"name":"National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Canevelli","sequence":"additional","affiliation":[{"name":"National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy"},{"name":"Department of Human Neuroscience, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Piscopo","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Italian National Institute of Health, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Vanacore","sequence":"additional","affiliation":[{"name":"National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-220046_ref1","doi-asserted-by":"crossref","first-page":"e12179","DOI":"10.1002\/trc2.12179","article-title":"Alzheimer\u2019s disease drug development pipeline: 2021","volume":"7","author":"Cummings","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-220046_ref2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000511506","article-title":"lessons learnt from the second generation of anti-amyloid monoclonal antibodies clinical trials","volume":"49","author":"Tian Hui Kwan","year":"2020","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-220046_ref4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jamaneurol.2021.3126","article-title":"US Food and Drug Administration approval of Aducanumab-Is amyloid load a valid surrogate end point for Alzheimer disease clinical trials?","volume":"78","author":"Planche","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-220046_ref5","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of amyloid and tau with cognition in preclinical Alzheimer disease: A longitudinal study","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-220046_ref6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220046_ref7","first-page":"146","article-title":"The future of anti-amyloid trials","volume":"7","author":"Aisen","year":"2020","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-220046_ref8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11481-016-9722-5","article-title":"Safety and efficacy of anti-amyloid-\u03b2 immunotherapy in Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"12","author":"Penninkilampi","year":"2017","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.3233\/JAD-220046_ref9","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/acn3.469","article-title":"Efficacy and safety of anti-amyloid-\u03b2 immunotherapy for Alzheimer\u2019s disease: A systematic review and network meta-analysis","volume":"4","author":"Mo","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"10.3233\/JAD-220046_ref10","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.25011\/cim.v42i1.32393","article-title":"Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer\u2019s disease: A systematic review and network meta-analysis","volume":"42","author":"Foroutan","year":"2019","journal-title":"Clin Invest Med"},{"key":"10.3233\/JAD-220046_ref11","doi-asserted-by":"crossref","first-page":"101339","DOI":"10.1016\/j.arr.2021.101339","article-title":"Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer\u2019s disease","volume":"68","author":"Avgerinos","year":"2021","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-220046_ref12","doi-asserted-by":"crossref","first-page":"n156","DOI":"10.1136\/bmj.n156","article-title":"Effect of reductions in amyloid levels on cognitive change in randomized trials: Instrumental variable meta-analysis","volume":"372","author":"Ackley","year":"2021","journal-title":"BMJ"},{"issue":"Suppl 9","key":"10.3233\/JAD-220046_ref13","doi-asserted-by":"crossref","first-page":"e057778","DOI":"10.1002\/alz.057778","article-title":"Cognitive outcomes of anti-amyloid-\u03b2 monoclonal antibodies in patients with Alzheimer\u2019s disease: A systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Lahoz Fernandez","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220046_ref15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.3233\/JAD-220046_ref16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13195-016-0177-y","article-title":"First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer\u2019s disease","volume":"8","author":"Delnomdedieu","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220046_ref17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","article-title":"First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer\u2019s disease","volume":"2","author":"Ferrero","year":"2016","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-220046_ref18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.3233\/JAD-220046_ref19","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/ggi.12516","article-title":"Safety and pharmacokinetics of bapineuzumab in a single ascending-dose study in Japanese patients with mild to moderate Alzheimer\u2019s disease","volume":"16","author":"Arai","year":"2016","journal-title":"Geriatr Gerontol Int"},{"key":"10.3233\/JAD-220046_ref20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/WAD.0b013e3181c53b00","article-title":"A single ascending dose study of bapineuzumab in patients with Alzheimer disease","volume":"24","author":"Black","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-220046_ref21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpdd.584","article-title":"Pharmacokinetics, pharmacodynamics, and safety of subcutaneous bapineuzumab: A single-ascending-dose study in patients with mild to moderate Alzheimer disease","volume":"8","author":"Lu","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.3233\/JAD-220046_ref22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer\u2019s disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220046_ref23","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.3233\/JAD-220046_ref24","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3233\/JAD-160369","article-title":"A phase II, randomized, double-blind, placebo-controlled study of safety, pharmacokinetics, and biomarker results of subcutaneous bapineuzumab in patients with mild to moderate Alzheimer\u2019s disease","volume":"54","author":"Brody","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220046_ref25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-220046_ref26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220046_ref27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13195-016-0193-y","article-title":"Long-term safety and tolerability of bapineuzumab in patients with Alzheimer\u2019s disease in two phase 3 extension studies","volume":"8","author":"Ivanoiu","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220046_ref28","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3233\/JAD-200134","article-title":"Safety, tolerability, and pharmacokinetics of Crenezumab in patients with mild-to-moderate Alzheimer\u2019s disease treated with escalating doses for up to 133 weeks","volume":"76","author":"Guthrie","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220046_ref29","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JAD-220046_ref30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE)","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220046_ref31","doi-asserted-by":"crossref","first-page":"e12112","DOI":"10.1002\/trc2.12112","article-title":"Donanemab (LY3002813) dose-escalation study in Alzheimer\u2019s disease","volume":"7","author":"Lowe","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-220046_ref32","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-220046_ref33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401\u2013a clinical study in Alzheimer\u2019s disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220046_ref34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220046_ref35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-220046_ref36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220046_ref37","doi-asserted-by":"crossref","first-page":"e0098153","DOI":"10.1371\/journal.pone.0098153","article-title":"First administration of the Fc-attenuated anti-\u03b2 amyloid antibody GSK933776 to patients with mild Alzheimer\u2019s disease: A randomized, placebo-controlled study","volume":"10","author":"Andreasen","year":"2015","journal-title":"PloS One"},{"key":"10.3233\/JAD-220046_ref38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/alzrt249","article-title":"Modulation of \u03b2-amyloid by a single dose of GSK933776 in patients with mild Alzheimer\u2019s disease: A phase I study","volume":"6","author":"Leyhe","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220046_ref39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3233\/JAD-180925","article-title":"Pharmacokinetics and pharmacodynamics of LY2599666, a PEG-linked antigen binding fragment that targets soluble monomer amyloid-\u03b2","volume":"68","author":"Li","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220046_ref40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNF.0b013e31827db49b","article-title":"Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: A phase I, randomized, placebo-controlled, double-blind, dose-escalation study","volume":"36","author":"Landen","year":"2013","journal-title":"Clin Neuropharmacol"},{"key":"10.3233\/JAD-220046_ref41","doi-asserted-by":"crossref","first-page":"911","DOI":"10.5414\/CP201816","article-title":"Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer\u2019s disease: A multicenter, randomized, double-blind, placebo-controlled, dose-escalation study","volume":"51","author":"Miyoshi","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.3233\/JAD-220046_ref42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trci.2017.04.003","article-title":"Multiple-dose ponezumab for mild-to-moderate Alzheimer\u2019s disease: Safety and efficacy","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-220046_ref43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.trci.2017.05.003","article-title":"Ponezumab in mild-to-moderate Alzheimer\u2019s disease:Randomized phase II PET-PIB study","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-220046_ref44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/WNF.0b013e3181cb577a","article-title":"Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease","volume":"33","author":"Siemers","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.3233\/JAD-220046_ref45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/WNF.0b013e31823a13d3","article-title":"Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid \u03b2 monoclonal antibody solanezumab in Japanese and white patients with mild to moderate Alzheimer disease","volume":"35","author":"Uenaka","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.3233\/JAD-220046_ref46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","article-title":"Safety and biomarker effects of solanezumab in patients with Alzheimer\u2019s disease","volume":"8","author":"Farlow","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220046_ref47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-220046_ref48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.trci.2015.06.006","article-title":"Delayed-start analysis: Mild Alzheimer\u2019s disease patients in solanezumab trials, 3.5 years","volume":"1","author":"Liu-Seifert","year":"2015","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-220046_ref49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-220046_ref50","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer\u2019s disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-220046_ref51","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jama.2015.292","article-title":"Sharing clinical trial data: Maximizing benefits, minimizing risk","volume":"313","author":"Lo","year":"2015","journal-title":"JAMA"},{"key":"10.3233\/JAD-220046_ref52","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1056\/NEJMp2034518","article-title":"Leveraging open science to accelerate research","volume":"384","author":"Kadakia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-220046_ref53","doi-asserted-by":"crossref","first-page":"e1632","DOI":"10.1212\/WNL.0000000000011542","article-title":"Longitudinal accumulation of cerebral microhemorrhages in dominantly inherited Alzheimer disease","volume":"96","author":"Joseph-Mathurin","year":"2021","journal-title":"Neurology"},{"key":"10.3233\/JAD-220046_ref54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s40478-016-0399-z","article-title":"Post-mortem histopathology underlying \u03b2-amyloid PET imaging following flutemetamol F 18 injection","volume":"4","author":"Ikonomovic","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JAD-220046_ref55","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2967\/jnumed.120.250290","article-title":"Toward a universal readout for 18F-labeled amyloid tracers: The CAPTAINs Study","volume":"62","author":"Bischof","year":"2021","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-220046_ref56","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00259-015-3228-x","article-title":"Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"43","author":"Morris","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-220046_ref57","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3233\/JAD-191109","article-title":"Comparison of diagnostic performances between cerebrospinal fluid biomarkers and amyloid PET in a clinical setting","volume":"74","author":"Jung","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220046_ref58","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3233\/JAD-170327","article-title":"The cerebrospinal fluidA\u03b21-42\/A\u03b21-40 ratio improves concordance withamyloid-PET for diagnosing Alzheimer\u2019s disease in a clinical setting","volume":"60","author":"Niemantsverdriet","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220046_ref59","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1001\/jama.2021.3854","article-title":"Evaluation of Aducanumab for Alzheimer disease: Scientific evidence and regulatory review involving efficacy, safety, and futility","volume":"325","author":"Alexander","year":"2021","journal-title":"JAMA"},{"key":"10.3233\/JAD-220046_ref60","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: Follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.3233\/JAD-220046_ref61","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/brain\/awz142","article-title":"Persistent neuropathological effects 14 years following amyloid-\u03b2 immunization in Alzheimer\u2019s disease","volume":"142","author":"Nicoll","year":"2019","journal-title":"Brain"},{"key":"10.3233\/JAD-220046_ref62","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJMp2110468","article-title":"Revisiting FDA Approval of Aducanumab","volume":"385","author":"Alexander","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-220046_ref63","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMc2111960","article-title":"An appropriate use of accelerated approval - Aducanumab for Alzheimer\u2019s disease","volume":"385","author":"Dunn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-220046_ref64","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1212\/WNL.0000000000012452","article-title":"Prescribing Aducanumab in the face of meager efficacy and real risks","volume":"97","author":"Knopman","year":"2021","journal-title":"Neurology"},{"key":"10.3233\/JAD-220046_ref65","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1212\/WNL.0000000000012451","article-title":"Aducanumab, amyloid lowering, and slowing of Alzheimer disease","volume":"97","author":"Salloway","year":"2021","journal-title":"Neurology"},{"key":"10.3233\/JAD-220046_ref66","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/jamainternmed.2020.1097","article-title":"FDA acceptance of surrogate end points for cancer drug approval: 1992\u20132019","volume":"180","author":"Chen","year":"2020","journal-title":"JAMA Intern Med"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-220046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:05:38Z","timestamp":1777370738000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-220046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":64,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-220046","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]}}}